DPP4 and Stroke: However, the risks of the primary and secondary endpoints were similar between treatment groups even in patients at high risk for hospitalization for heart failure [148], suggesting that DPP4 inhibition by saxagliptin does not increase death, myocardial infarction, or stroke even in those with increased risk for heart failure [149].